DOCSLIB.ORG

Optimization of Separation and Online Sample Concentration of N,N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Optimization of Separation and Online Sample Concentration of N,N J. Sep. Sci. 2009, 32, 441 – 445 M.-J. Wang et al. 441 Man-Juing Wang1 Original Paper Chih-Hsin Tsai1 Wei-Ya Hsu1 Ju-Tsung Liu2 Optimization of separation and online sample Cheng-Huang Lin1 concentration of N,N-dimethyltryptamine and 1Department of Chemistry, related compounds using MEKC National Taiwan Normal University, Taipei, Taiwan The optimal separation conditions and online sample concentration for N,N-dime- 2Forensic Science Center, Military Police Command, Department of thyltryptamine (DMT) and related compounds, including a-methyltryptamine Defense, Taipei, Taiwan (AMT), 5-methoxy-AMT (5-MeO-AMT), N,N-diethyltryptamine (DET), N,N-dipropyltrypt- amine (DPT), N,N-dibutyltryptamine (DBT), N,N-diisopropyltryptamine (DiPT), 5- methoxy-DMT (5-MeO-DMT), and 5-methoxy-N,N-DiPT (5-MeO-DiPT), using micellar EKC (MEKC) with UV-absorbance detection are described. The LODs (S/N = 3) for MEKC ranged from 1.0 l 1.8 lg/mL. Use of online sample concentration methods, including sweeping-MEKC and cation-selective exhaustive injection-sweep-MEKC (CSEI-sweep-MEKC) improved the LODs to 2.2 l 8.0 ng/mL and 1.3 l 2.7 ng/mL, respectively. In addition, the order of migration of the nine tryptamines was inves- tigated. A urine sample, obtained by spiking urine collected from a human volun- teer with DMT, was also successfully examined. Keywords: MEKC / Sweeping-MEKC / Tryptamine / Received: September 8, 2008; revised: October 31, 2008; accepted: November 2, 2008 DOI 10.1002/jssc.200800492 1 Introduction diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-dibutyltryptamine (DBT), DiPT, and 5-methoxy-N,N- N,N-dimethyltryptamine (DMT legal status: class A, UK; DMT (5-MeO-DMT) remain unscheduled. Hence, detection schedule I, US), a powerful psychoactive substance, is of these tryptamine-like drugs, which may be produced both a naturally occurring tryptamine and a potent psy- in underground laboratories and sold on the streets, is chedelic drug. Structurally, it is analogous to the neuro- an analytical challenge, not only because their chemical transmitter serotonin and other psychedelic trypt- structures are similar, but also because their levels in bio- amines, such as a-methyltryptamine (AMT), 5-methoxy- logical fluids are very low. From the point of view of AMT (5-MeO-AMT), and 5-methoxy-N,N-diisopropyltrypt- screening for and confirmation of illicit tryptamine amine (5-MeO-DiPT). These tryptamine derivatives are derivatives, more detailed information on separation illegal drugs that are listed on Schedule I of the Con- and detection of these compounds is highly desirable. trolled Substances Act (US). It should be noted that substi- Currently, GC-EI/MS [1–7], LC-ESI/MS [8–11], and CE [12– tutions to the tryptamine molecule give rise to a group 13] are the most popular and well-developed methods for of related compounds; the degree of alkylation of the identification of tryptamine derivatives. Each of these side-chain nitrogen of tryptamine has a significant effect methods has unique advantages and disadvantages with on its psychoactivity. However, a number of tryptamine respect to sensitivity, precision, and simplicity of use. In derivatives, the so-called designer drugs, such as N,N- our previous research, we have ever compared the analyt- ical sensitivity, selectivity, time, cost, and the order of Correspondence: Professor Cheng-Huang Lin, Department of migration based on different separation techniques (GC, Chemistry, National Taiwan Normal University, 88 Section 4, HPLC, and CE, respectively) [14]. In this study, mixtures of Tingchow Road, Taipei, Taiwan DMT, and related compounds, including AMT, 5-MeO- E-mail: [email protected] AMT (primary amines), DET, DPT, DiPT, DBT (various Fax: +886-2-2932-4249 degree of alkylation of the side-chain nitrogen in trypt- Abbreviations: AMT, a-methyltryptamine; BGS, background sol- amine), 5-MeO-AMT, 5-MeO-DMT, and 5-MeO-DiPT (5- ution; CSEI-sweep-MEKC, cation-selective exhaustive injection- methoxy-tryptamines) were used in the CE separation sweep-micellar EKC; DBT, N,N-dibutyltryptamine; DET, N,N-di- experiments. Using MEKC, a set of operational condi- ethyltryptamine; DiPT, N,N-diisopropyltryptamine; DMT, N,N-di- methyltryptamine; DPT, N,N-dipropyltryptamine; 5-MeO-AMT, 5- tions was selected for investigation of migration order. methoxy-AMT; 5-MeO-DMT, 5-methoxy-DMT Furthermore, in attempts to improve the sensitivity of i 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.jss-journal.com 442 M.-J. Wang et al. J. Sep. Sci. 2009, 32, 441 – 445 detection, online sample concentration techniques, including sweeping-MEKC and cation-selective exhaus- tive injection-sweep-micellar EKC (CSEI-sweep-MEKC) [15–24], were applied. A urine sample was obtained by spiking urine collected from a human volunteer with DMT. After liquid–liquid extraction, the sample was examined using the sweeping-MEKC mode under opti- mized conditions. The extraction procedures used for the urine sample and the CE conditions were also opti- mized and are reported here. 2 Experimental 2.1 Reagents DMT, AMT, 5-MeO-AMT, and 5-MeO-DiPT were generously donated by the Military Police Command, Forensic Sci- ence Center, Taiwan. DET, DPT, DBT, DiPT, and 5-MeO- DMT were synthesized in this study. The procedures for their synthesis have been described previously by Shul- gin and Shulgin, TIHKAL (Tryptamines I Have Known and Loved) [25]. Following synthesis, the final products were identified using NMR and IR, and were verified using GC/ MS. SDS was purchased from Acros (Belgium). All other chemicals were of analytical grade and were obtained from commercial sources. 2.2 Apparatus The CE setup was identical to that used in our previous study [26]. Briefly, a high-voltage power supply (Model Figure 1. UV absorption spectra and molecular structures of RR30-2R, Gamma, FL, USA) was used to drive electropho- the nine tryptamines, and the abbreviations used in this resis, and a 50 lm id fused-silica capillary column (J&W paper. Scientific, CA, USA) was used for separation (total/effec- tive length of capillary: 80/67 cm). The sample solution was hydrodynamically injected by raising the sample res- 3 Results and discussion ervoir to provide the height difference for the injection length. A UV-detector (CE-971 UV, Jasco, Japan) was used 3.1 MEKC for analyte determination at a detection wavelength of Figure 1 shows the UV absorption spectra and molecular 280 nm. structures of the nine tryptamines used in this study; spectra a–i correspond to DMT, DET, DPT, DBT, AMT, DiPT, 5-MeO-AMT, 5-MeO-DMT, and 5-MeO-DiPT, respec- 2.3 Urine extraction procedure tively. Maximum absorption was observed at l280 nm. In a glass tube, a 1 mL aliquot of a clean urine sample The 5-MeO-AMT, 5-MeO-DMT, and 5-MeO-DiPT produced obtained from a human volunteer, was spiked with spectral patterns that differed from those of the other 25 ng DMT. The spiked urine sample was made alkaline compounds. These spectra are useful for online identifi- by the addition of 2 mg of potassium carbonate and then cation if a CCD detector is available. Figure 2 shows typi- was shaken for 1 min. 4 mL of hexane/dichloromethane cal MEKC/UV-absorption electropherograms for the nine (v/v 3:1) were added, and gently mixed for 5 min, fol- tryptamines, each measured at a concentration of 10 lg/ lowed by centrifugation. The upper layer was collected mL, using SDS as the surfactant. The CE buffer consisted (3 mL) and the organic phase was evaporated to dryness. of a mixture of 75 mM SDS and 50 mM NaH2PO4. The The residue was dissolved in 0.05 mL of ethanol for the volumetric ratio of water, methanol, and ACN (i.e., water/ subsequent CE separation. The extraction efficiency of methanol/ACN by volume) for electropherograms a–d, this procedure for DMT was 56.8 l 6.2% (n = 5). were as follows: a, 80:20:0; b, 70:30:0; c, 70:0:30; d, i 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.jss-journal.com J. Sep. Sci. 2009, 32, 441 – 445 Electrodriven Separation 443 Figure 2. Typical MEKC/UV-absorption electropherogram for the nine tryptamines using SDS as surfactant; sample concentration, 10 lg/1 mL of methanol. The CE buffer con- sisted of 75 mM SDS and 50 mM NaH PO in a mixture of 2 4 Figure 3. (A) Sweeping-MEKC/UV-absorption electrophero- water/methanol/ACN (electropherograms a–d, by volume a, gram for the nine tryptamines. Sample concentration, 0.5 lg 80:20:0; b, 70:30:0; c, 70:0:30; d, 65:30:5, respectively); the in BGS (without SDS). Conditions: Phosphate buffer pH of which was adjusted to l2.2* using H PO . The applied 3 4 (50 mM, pH 2.2) in an ACN/methanol/water (5:30:65 by vol- voltage was –15 kV. ume) solution containing 75 mM SDS. The applied voltage was –15 kV. The samples were prepared in matrices (elec- tropherograms, 50 mM NaH2PO4 aqueous solution). Sample 65:30:5. The pH of the water/organic solvent mixture was injection length, 45 cm; total/effective length of the capillary, adjusted to l2.2*, using H3PO4. As seen in electrophero- 80/67 cm. (B) CSEI-sweep-MEKC electropherogram for the grams a and b, use of methanol alone does not result in nine tryptamines. Sample concentration, 50 ng in 1 mL BGS (without SDS). Conditions: The capillary was first filled with complete separation. When ACN was used instead of background buffer, followed by injection of a high conductiv- methanol, separation efficiency improved, although the ity buffer (approximately a 10 cm length of capillary with separation time increased.
Load more

Recommended publications
  • Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatograph
    applied sciences Article Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatography Mass Spectrometry, Electrospray and Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Bo-Hong Chen, Ju-Tsung Liu, Hung-Ming Chen, Wen-Xiong Chen and Cheng-Huang Lin * Department of Chemistry, National Taiwan Normal University, 88 Sec. 4 Tingchow Road, Taipei 11677, Taiwan; [email protected] (B.-H.C.); [email protected] (J.-T.L.); [email protected] (H.-M.C.); [email protected] (W.-X.C.) * Correspondence: [email protected]; Tel.: +886-2-7734-6170; Fax: +886-2-2932-4249 Received: 18 April 2018; Accepted: 19 June 2018; Published: 22 June 2018 Abstract: Characteristic mass fragmentation of 20 phenethylamine/tryptamine standards were investigated and compared by means of matrix assisted laser desorption/time-of-flight mass spectrometry (MALDI/TOFM), gas chromatography–electron ionization–mass spectrometry (GC-EI/MS) and liquid chromatography–electrospray ionization/mass spectrometry (LC-ESI/MS) + methods. As a result, three characteristic peaks ([M] and fragments from the Cβ-Cα bond breakage) were found to be unique and contained information useful in identifying 2C series compounds based on the GC-EI/MS method. We found that the protonated molecular ion ([M+H]+) and two types of fragments produced from the α-cleavage and β-cleavage processes were useful mass spectral information in the rapid screening and confirmation of phenethylamine and tryptamine derivatives when ESI/MS and MALDI/TOFMS methods were applied. This assay was successfully used to determine samples that contain illicit drugs. Keywords: phenethylamine; tryptamine; MALDI/TOFMS; GC-EI/MS; LC-ESI/MS 1.
    [Show full text]
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
    [Show full text]
  • Virginia Acts of Assembly -- 2021 Special Session I
    VIRGINIA ACTS OF ASSEMBLY -- 2021 SPECIAL SESSION I CHAPTER 110 An Act to amend and reenact §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia, relating to industrial hemp; emergency. [H 2078] Approved March 12, 2021 Be it enacted by the General Assembly of Virginia: 1. That §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia are amended and reenacted as follows: § 3.2-4112. Definitions. As used in this chapter, unless the context requires a different meaning: "Cannabis sativa product" means a product made from any part of the plant Cannabis sativa, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, with a concentration of tetrahydrocannabinol that is greater than that allowed by federal law. "Deal" means to buy temporarily possess industrial hemp grown in compliance with state or federal law and to sell such industrial hemp to a person who that (i) processes industrial hemp in compliance with state or federal law or has not been processed and (ii) sells industrial hemp to a person who processes industrial hemp in compliance with state or federal law was not grown and will not be processed by the person temporarily possessing it.
    [Show full text]
  • A General Approach to the Screening and Confirmation of Tryptamines And
    Available online at www.sciencedirect.com Talanta 74 (2008) 512–517 A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation Bo-Hong Chen a, Ju-Tsung Liu b, Wen-Xiong Chen a, Hung-Ming Chen a, Cheng-Huang Lin a,∗ a Department of Chemistry, National Taiwan Normal University, 88 Sec. 4, Tingchow Road, Taipei, Taiwan b Forensic Science Center, Military Police Command, Department of Defense, Taipei, Taiwan Received 6 March 2007; received in revised form 12 June 2007; accepted 13 June 2007 Available online 19 June 2007 Abstract Certain characteristic fragmentations of tryptamines (indoleethylamine) and phenethylamines are described. Based on the GC–EI/MS, LC–ESI/ MS and MALDI/TOFMS, the mass fragmentations of 13 standard compounds, including ␣-methyltryptamine (AMT), N,N-dimethyltryptamine (DMT), 5-methoxy-␣-methyltryptamine (5-MeO-AMT), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-dibutyltryptamine (DBT), N,N-diisopropyltryptamine (DIPT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-methoxy-N,N-diisopropyltryptamine (5-MeO- DIPT), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (3,4-MDA), 3,4-methylenedioxymethamphetamine (3,4-MDMA) and 2- methylamino-1-(3,4-methylenedioxyphenyl)butane (MBDB), were compared. As a result, the parent ions of these analytes were hard to be obtained by GC/MS whereas the protonated molecular ions can be observed clearly by means of ESI/MS and MALDI/TOFMS. Furthermore, two major + + + + characteristic fragmentations, namely and ␣-cleavage ([M +H] → [3-vinylindole] ) and ␤-cleavage ([M +H] → [CH2N RN1RN2]), are produced when the ESI and MALDI modes are used, respectively. In the case of ESI/MS, the fragment obtained from ␣-cleavage is the major process.
    [Show full text]
  • M a P S • V O L U M E X I I I N U M B E R 2
    m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 1 2 m a p s • v o l u m e x i i i n u m b e r 2 • w i n t e r 2 0 0 3 Divine Spark The cover of this MAPS bulletin is an image from visionary artist Alex Grey’s triptych Holy Fire, which was inspired by one of Alex’s early MDMA experiences. We thought it was an appropriate choice to ex- press our emotions at obtaining Institutional Review Board (IRB) approval for Dr. Mithoefer's MAPS-sponsored MDMA/PTSD study (see page 7). The rest of the images on this page and on the back cover are from the 2003 Burning Man Festival, at which MAPS provided psychedelic emergency services. (Article on page 28). In the photo above, members of the Fire Conclave open the festivities at the Burning of the Man, the climax of the week-long festival. The photo below depicts the more somber burning of the Temple of Honor, at which Burning Man participants remember loved ones by leaving notes and tokens inside. As the temple burned, MAPS president Rick Doblin threw in the fire the original copies of the last set of documents about protocol design issues exchanged between MAPS and the IRB. This symbolized his hopes that we would finally move beyond the paperwork of the approval process to the therapeutic work of the study itself.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Designer Drugs: a Review
    WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chavan et al. World Journal of Pharmacy and Pharmaceutical Sciences SJIF Impact Factor 5.210 Volume 4, Issue 08, 297-336. Review Article ISSN 2278 – 4357 DESIGNER DRUGS: A REVIEW Dr. Suyash Chavan,MBBS*1 and Dr. Vandana Roy2 1MD, Resident Doctor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. 2MD, PhD Professor, Department of Pharmacology, Maulana Azad Medical College, New Delhi. ABSTRACT Article Received on 25 May 2015, Designer drugs‟ are psychoactive substances that mimic the effects of Revised on 16 June 2015, other banned illicit drugs but evade detection by law enforcing Accepted on 07 July 2015 agencies. This is because of modifications in the structure of the original psychoactive molecule. Originally developed as a way to *Correspondence for evade existing drug laws in the late 1960s, the synthesis and use of Author designer drugs has increased dramatically. They are advertised with Dr. Suyash Chavan innocuous names and are sold mostly over the internet, discreet outlets MD, Resident Doctor, Department of and at entertainment clubs. Victims may exhibit symptoms similar to Pharmacology, Maulana the effects of the illegal drug that these synthetic drugs mimic, Azad Medical College, however, the exact culprit drug is not detected due to structural New Delhi. modifications in the new drug. Overdose of these drugs may lead to serious adverse effects that can be life threatening. Understanding the pharmacology and toxicology of these agents is essential to facilitate their detection and to provide better medical care for patients suffering from adverse effects due to their consumption.
    [Show full text]
  • Newer Unregulated Drugs Look-Up Table
    Newer Unregulated Drugs Look-up Table List Name Chemical Name/AKA Type of drug Notes Stimulant Regulation under MDA (Sch. 1 or TCDO) Stimulant/Hallucinogen Regulation under MDA (Sch. 2-5) Hallucinogen Regulated by PSA Depressant Exempt Cannabinoid Uncertain/requires clarification 1P-LSD 1-propionyl-lysergic acid diethylamide Hallucinogen An LSD analogue that side-stepped MDA and was on sale as an NPS; now covered by the PSA. 2-AI 2-Aminoindane Stimulant, amphetamine analogue Reported in the UK in 2011 by the Forensic Early 2-MAI N-methyl-2-Aminoindane Warning System (FEWS). Had been on sale via number MMAI of online stores; covered by PSA. 2-MeO-ketamine Methoxyketamine Related to methoxetamine so a relative Believed to have been made a CD at the same time as Methoxieticyclidine of ketamine – i.e. a dissassociative Methoxetamine anaesthetic hallucinogen 2C-B-BZP (1-(4-bromo-2,5- Piperazine family; stimulant Class B dimethoxybenzyl)piperazine) 2-DPMP Desoxypipadrol stimulant Strong and long acting stimulant; reported duration of 2-diphenylmethylpiperidine effect 24-28hrs or more and effective at very low doses. Had been on sale in the UK and cropped up in branded “Ivory Wave” and in other compounds. Linked to fatalities. Class B, Sch1. 2-NE1 APICA Synthetic cannabinoid receptor agonist 3rd generation SCRA. Covered by PSA SDB-001 N-(1-adamantyl)-1-pentyl-1H-indole-3- carboxamide 3-FPM Phenzacaine Stimulant, euphoriants Sibling of the controlled drug Phenmetrazine. Emerged PAL-593 2015. Covered by PSA 2-(3-fluorophenyl)-3-methylmorpholine 3-hydroxyphenazepam Benzo, GABA-nergic PSA 3-MeO-PCE (3-methoxyeticyclidine) Related to methoxetamine so a relative Probably regulated under the same clause that made of ketamine – i.e.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Urinary Excretion Profiles of 5-Methoxy-N,N
    Journal of Health Science, 53(5) 585–590 (2007) 585 Urinary Excretion Profiles of 60 hr for 6-OH-5-MeO-DIPT and 5-MeO-NIPT. 5-Methoxy-N,N- Key words —— 5-methoxy-N,N-diisopropyltryptamine, diisopropyltryptamine and Its excretion profile, enzymatic hydrolysis, urine analysis, Relevant Metabolites in Humans forensic science ∗ Tooru Kamata, Munehiro Katagi, INTRODUCTION Hiroe Kamata, Akihiro Miki, Noriaki Shima, Kei Zaitsu, Mayumi Nishikawa, 5-Methoxy-N,N-diisopropyltryptamine (5- and Hitoshi Tsuchihashi MeO-DIPT) (Fig. 1) is a psychotomimetic tryptamine derivative first synthesized and re- Forensic Science Laboratory, Osaka Prefectural Police Head- ported by Shulgin and Carter in 1980.1) It causes quarters, 1–3–18, Hommachi, Chuo-ku, Osaka 541–0053, mydriasis, and high dosage produces nausea, jaw Japan clenching, muscle tension, and overt hallucina- (Received March 5, 2007; Accepted June 14, 2007) tions with both auditory and visual distortions.2) 5-MeO-DIPT has been abused since the 1990s in 5-Methoxy-N,N-diisopropyltryptamine (5-MeO- many countries under the name “Foxy” or “Foxy DIPT), a psychotomimetic tryptamine derivative, Methoxy.” In 2005, this drug was banned in Japan and its relevant metabolites have been determined in under the Narcotics and Psychotropics Control Law eleven urine specimens from six 5-MeO-DIPT users, to prevent its rapid spread as a “recreational drug.” and their excretion profiles have been investigated For the control of drugs of abuse, careful inves- by gas chromatography/mass spectrometry (GC/MS) tigation on the metabolism and excretion of the drug and liquid chromatography/mass spectrometry and relevant metabolites in humans, as well as the (LC/MS).
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]